HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Ayalasomayajula, S. P. Articles by Dole, W. P. Search for Related Content PubMed PubMed Citation Articles by Ayalasomayajula, S. P. Articles by Dole, W. P. Social Bookmarking                         What's this?

Effect of Clopidogrel on the Steady-State Pharmacokinetics of Fluvastatin

From Novartis Pharmaceuticals, East Hanover, New Jersey.

This study assessed the effects of clopidogrel, a CYP 2C9 inhibitor, on fluvastatin pharmacokinetics in healthy volunteers. The effects of combined clopidogrel-fluvastatin treatment on platelet function were also determined. Subjects received 80 mg fluvastatin (extended-release formulation) alone on days 1 through 9, 80 mg fluvastatin and 300 mg clopidogrel (loading dose) on day 10, and 80 mg fluvastatin and 75 mg clopidogrel (maintenance dose) on days 11 through 19. Compared to treatment with fluvastatin alone, fluvastatin AUC was similar and C_max increased marginally (15.7%) with concomitant treatment with clopidogrel. Platelet aggregation was inhibited by clopidogrel by 33% two hours after the loading dose and by 47% at steady state, similar to that reported for clopidogrel alone treatment. The authors conclude that coadministration of fluvastatin and clopidogrel has no clinically relevant effect on fluvastatin pharmacokinetics or on platelet inhibition by clopidogrel.

Key Words: Clopidogrel • fluvastatin • pharmacokinetics • drug interactions

Address for reprints: Address for correspondence: Surya P. Ayalasomayajula, PhD, Novartis Pharmaceuticals, One Health Plaza, East Hanover, NJ 07936; e-mail: surya.ayalasomayajula{at}novartis.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa Interaction between statins and clopidogrel: is there anything clinically relevant? QJM, December 1, 2008; 101(12): 915 - 925. [Abstract] [Full Text] [PDF]

				P. Gareri, P. De Fazio, L. Gallelli, S. De Fazio, A. Davoli, G. Seminara, A. Cotroneo, and G. De Sarro Venlafaxine-Propafenone Interaction Resulting in Hallucinations and Psychomotor Agitation Ann. Pharmacother., March 1, 2008; 42(3): 434 - 438. [Abstract] [Full Text] [PDF]